DR. FRED E COHEN, M.D.
Osteopathic Medicine at California St, San Francisco, CA

6617119, Sep 9, 2003

Jul 9, 2001

09/901865

Stanley B. Prusiner - San Francisco CA
Jiri G. Safar - Concord CA
Fred E. Cohen - San Francisco CA

The Regents of the University of California - Oakland CA

G01N 3353

435 71, 435 5

Assay methodology of the invention allows for: (1) determining if a sample contains a conformation of a protein which is associated with disease and the concentration and amount of such if present; (2) determining the amount of protease resistant disease related protein in a sample and by subtracting that amount from the total amount of disease related protein present determining the amount of protease sensitive disease protein in the sample; and (3) determining the strain and incubation time of a disease related protein by (i) relating the relative amounts of protease resistant and protease sensitive protein to known strains to thereby determine the strain; and (ii) plotting the concentration of protease sensitive protein on a graph of incubation time versus concentration of protease sensitive protein for known strains to predict the incubation time of an unknown strain of pathogenic protein in a sample.

6602672, Aug 5, 2003

Sep 25, 2000

09/669516

Stanley B. Prusiner - San Francisco CA
Glenn C. Telling - San Francisco CA
Fred E. Cohen - San Francisco CA
Michael R. Scott - San Francisco CA

The Regents of the University of California - Oakland CA

G01N 3353

435 71, 435 691, 4353201, 435325, 4352523, 536 231, 530350

DNA constructs are provided of epitope-tagged proteins or protein fragments which are conveniently purified with immunoaffinity chromatography such as epitope-tagged prion proteins (PrP). Transgenic animals expressing an epitope-tagged protein are provided, including transgenic animals expressing epitope-tagged PrP. Methods for distinguishing between the conformational shapes of a protein and a convenient method for isolating a tagged protein by immunoaffinity chromatographic methods are provided.

5849695, Dec 15, 1998

Jan 13, 1993

7/972466

Fred E. Cohen - San Francisco CA
Robert A. Nissenson - Burlingame CA
Gordon J. Strewler - San Francisco CA

The Regents of the University of California - Oakland CA

A61K 3829, A61K 3804

514 12

The present invention relates polypeptide analogs which have agonist or antagonist or tissue selection properties relative to parathyroid hormone (PTH), parathyroid hormone-like protein (PLP) or parathyroid-related protein (PTHrP). The serine amino acid at position 3, the glutamine amino acid at position 6, the histidine amino acid at position 9 or combinations thereof are substituted by other natural or synthetic amino acids. Preferably, a human PTH fragment of about 34 amino acids is sufficient for pharmacological activity. These polypeptides are useful as agonists or antagonists in the treatment of a human being for disease conditions of cancer, osteoporosis, hypercalcemia, or hyperparathyroid disease conditions. The invention also concerns a method of performing certain assays using the modified peptides, and based on the results of the assays falling within preset limits, selecting those modified peptides which shall be useful in the treatment of disease conditions.

5739170, Apr 14, 1998

Mar 30, 1995

8/413337

Fred E. Cohen - San Francisco CA
James H. McKerrow - San Francisco CA
George L. Kenyon - San Francisco CA
Zhe Li - Malden MA
Xiaowu Chen - San Francisco CA
Baoqing Gong - San Francisco CA
Rongshi Li - San Diego CA

The Regents of the University of California - Oakland CA

A61K 3112, A61K 31135

514685

Compositions and methods are disclosed for treating a patient infected with a metazoan parasite by inhibiting the enzymatic action of the metazoan parasite protease, wherein there is employed at least one compound of formula I A--X--B wherein A is a substituted or unsubstituted homoaromatic ring system comprising one to three rings which bind to at least one of the S2, S1 and S1' subsites; B is a substituted or unsubstituted homoaromatic ring system comprising one to three rings which bind to at least one of the S1', S1 and S2 subsites; and X is --C. dbd. C--C(. dbd. O)--. These compositions and methods have particular utility in the treatment of schistosomiasis, malaria, and other infectious diseases.

6897240, May 24, 2005

May 8, 2003

10/431714

Fred E. Cohen - San Francisco CA, US
Xiaohui Du - Los Angeles CA, US
Chun Guo - Shenyang, CN
James H. McKerrow - San Francisco CA, US

The Regents of the University of California - Oakland CA

A61K031/125, C07C337/00, A61P331/00

514582, 514590, 5142387, 564 18, 564 20, 564 34, 544162

The present invention relates to thio semicarbazone and semicarbazone inhibitors of cysteine proteases and methods of using such compounds to prevent and treat protozoan infections such as trypanosomiasis, malaria and leishmaniasis. The compounds also find use in inhibiting cysteine proteases associated with carcinogenesis, including cathepsins B and L.

5750361, May 12, 1998

Nov 2, 1995

8/556823

Stanley B. Prusiner - San Francisco CA
Fred E. Cohen - San Francisco CA

The Regents of the University of California - Oakland CA

C12Q 137, G01N 3100, G01N 2100, G01N 122

435 23

Prion protein (PrP) peptides having at least one. alpha. -helical domain and forming a random coil conformation in aqueous solutions bind cellular PrP (PrP. sup. C) to form a complex having characteristics of the scrapie isoform (PrP. sup. Sc). Methods for screening compounds able to inhibit or decrease the binding of PrP peptides to PrP. sup. C are disclosed, as well as methods for assaying PrP. sup. Sc.